Royalty Pharma ROA 2019-2021 | RPRX
Current and historical return on assets (ROA) values for Royalty Pharma (RPRX) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
|Royalty Pharma ROA - Return on Assets Historical Data
||TTM Net Income
||Return on Assets
||Finance - Miscellaneous Services
Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK.